Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Deal Summary 8
2.1 Pharmaceuticals & Healthcare, Global Deals Analysis, Q3 2010 8
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Value, Q3 2010 10
2.3 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2010 11
2.3.1 Reckitt Benckiser To Acquire SSL 11
2.3.2 Carlyle Group Completes Acquisition Of NBTY 11
2.3.3 Johnson & Johnson To Acquire Additional Stake In Crucell 11
2.3.4 Covance Enters Into An Agreement With Sanofi-Aventis 12
2.3.5 Gilead Sciences Completes Private Placement Of Senior Notes For $2,200 Million 12
3 Pharmaceuticals & Healthcare, Deals Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2010 13
3.1.1 Top M&A Deals in Q3 2010 14
3.1.2 Pharmaceuticals & Healthcare, Global M&A Deals, by Therapy Area, Q3 2009 - Q3 2010 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2010 16
3.2.1 Top Initial Public Offerings in Q3 2010 17
3.2.2 Top Secondary Offerings in Q3 2010 17
3.2.3 Top PIPE Deals in Q3 2010 17
3.2.4 Pharmaceuticals & Healthcare, Global, IPO deals, Q4 2009 – Q3 2010 18
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2009 – Q3 2010 19
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Q3 2010 20
3.3.1 Top Public Debt Offerings in Q3 2010 21
3.3.2 Top Private Debt Placements in Q3 2010 21
3.3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Q3 2009 - Q3 2010 22
3.4 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2010 23
3.4.1 Top Venture Financing Deals in Q3 2010 24
3.4.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2010 25
3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2009 - Q3 2010 26
3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2009 – Q3 2010 27
3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2010 28
3.5 Pharmaceuticals & Healthcare, Global Private Equity Deals, Q3 2010 29
3.5.1 Top Private Equity Deals in Q3 2010 30
3.5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2009 - Q3 2010 31
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2010 32
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2010 32
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2009 - Q3 2010 33
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2010 34
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Value, Q3 2010 35
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 38
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2010 40
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2010 40
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2010 42
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, Q3 2010 42
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2010 43
5.2.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 – Q3 2010 43
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2009 - Q3 2010 44
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), Q3 2009 - Q3 2010 46
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 47
6 Deal Summary by Therapy Area 48
6.1 Pharmaceuticals & Healthcare, Oncology Deals, Q3 2010 48
6.1.1 Oncology – Deals of the Quarter 49
6.2 Pharmaceuticals & Healthcare, Central Nervous System Deals, Q3 2010 50
6.2.1 Central Nervous System – Deals of the Quarter 51
6.3 Pharmaceuticals & Healthcare, Infectious Disease Deals, Q3 2010 52
6.3.1 Infectious Disease – Deals of the Quarter 53
6.4 Pharmaceuticals & Healthcare, Immunology Deals, Q3 2010 54
6.4.1 Immunology – Deals of the Quarter 55
6.5 Pharmaceuticals & Healthcare, Cardiovascular Deals, Q3 2010 56
6.5.1 Cardiovascular – Deals of the Quarter 57
6.6 Pharmaceuticals & Healthcare, Metabolic Disorders Deals, Q3 2010 58
6.6.1 Metabolic Disorders – Deals of the Quarter 59
6.7 Pharmaceuticals & Healthcare, Musculoskeletal Deals, Q3 2010 60
6.7.1 Musculoskeletal – Deals of the Quarter 61
6.8 Pharmaceuticals & Healthcare, Respiratory Deals, Q3 2010 62
6.8.1 Respiratory – Deals of the Quarter 63
6.9 Pharmaceuticals & Healthcare, Gastrointestinal Deals, Q3 2010 64
6.9.1 Gastrointestinal – Deals of the Quarter 65
6.10 Pharmaceuticals & Healthcare, Dermatology Deals, Q3 2010 66
6.10.1 Dermatology – Deals of the Quarter 67
7 Deal Summary by Geography 68
7.1 Pharmaceuticals & Healthcare, North America Region Deals, Q3 2010 68
7.1.1 North America – Deals of the Quarter 69
7.2 Pharmaceuticals & Healthcare, Europe Region Deals, Q3 2010 70
7.2.1 Europe – Deals of the Quarter 71
7.3 Pharmaceuticals & Healthcare, Asia-Pacific Deals, Q3 2010 72
7.3.1 Asia-Pacific – Deals of the Quarter 73
7.4 Pharmaceuticals & Healthcare, Rest of the World Deals, Q3 2010 74
7.4.1 Rest of the World – Deals of the Quarter 75
8 Pharmaceuticals & Healthcare, Top Advisors 76
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2009 - Q3 2010 76
8.2 Pharmaceuticals & Healthcare, Top Financial Advisors, Equity Offerings, Q4 2009 - Q3 2010 77
9 Further Information 78
9.1 Methodology 78
9.2 About GlobalData 78
9.3 Contact Us 79
9.4 Disclosure information 79
9.5 Disclaimer 79